Repligen (NASDAQ:RGEN) Announces Earnings Results

Repligen (NASDAQ:RGEN) posted its quarterly earnings results on Thursday. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03, Zacks reports. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen updated its FY 2025 guidance to 1.670-1.760 EPS.

Repligen Stock Down 2.3 %

RGEN stock opened at $158.99 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company’s 50-day moving average price is $155.22 and its two-hundred day moving average price is $148.79. Repligen has a 12 month low of $113.50 and a 12 month high of $203.13.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on RGEN shares. JPMorgan Chase & Co. lifted their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday. Wolfe Research assumed coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. StockNews.com cut shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday. TD Cowen started coverage on Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. Finally, Canaccord Genuity Group boosted their price target on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and an average price target of $183.36.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.